South Africa

**Population 2018**

<table>
<thead>
<tr>
<th>Number (thousands)</th>
<th>Rate (per 100 000 population)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total TB incidence</strong></td>
<td>520 (373–691)</td>
</tr>
<tr>
<td><strong>HIV-positive TB incidence</strong></td>
<td>306 (219–406)</td>
</tr>
<tr>
<td><strong>MDR/RR-TB incidence</strong></td>
<td>19 (12–28)</td>
</tr>
<tr>
<td><strong>HIV-negative TB mortality</strong></td>
<td>37 (35–39)</td>
</tr>
<tr>
<td><strong>HIV-positive TB mortality</strong></td>
<td>73 (51–99)</td>
</tr>
</tbody>
</table>

**Estimated proportion of TB cases with MDR/RR-TB, 2018**

- New cases: 3.4% (2.5–4.3)
- Previously treated cases: 7.1% (4.8–9.5)

**TB case notifications, 2018**

- Total new and relapse: 227 999
- - % tested with rapid diagnostics at time of diagnosis: 71%
- - % with known HIV status: 90%
- - % pulmonary: 89%
- - % bacteriologically confirmed: 70%
- - % children aged 0-14 years: 7%
- - % women: 37%
- - % men: 56%

**Universal health coverage and social protection**

- TB treatment coverage (notified/estimated incidence), 2018: 76% (57–110)
- TB patients facing catastrophic total costs: 22% (14–30)

**Drug-resistant TB care, 2018**

- % of bacteriologically confirmed TB cases tested for rifampicin resistance: 92%
- - New cases: 92%
- - Previously treated cases: 94%

**TB preventive treatment, 2018**

- % of HIV-positive people (newly enrolled in care) on preventive treatment: 65%
- % of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment: 59% (54–65)

**TB financing, 2019**

- National TB budget (US$ millions): 240
- Funding source: 87% domestic, 13% international, 0% unfunded

---

*Ranges represent uncertainty intervals*

**MDR** is TB resistant to rifampicin and isoniazid; **RR** is TB resistant to rifampicin

*Includes cases with unknown previous TB treatment history*

**Includes patients diagnosed before 2018 and patients who were not laboratory-confirmed**

---

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.

Generated: 2020-03-21

Data: www.who.int/tb/data